RAPT Therapeutics Inc
$ 57.93
0.00%
24 Feb - close price
- Market Cap 1,677,686,000 USD
- Current Price $ 57.93
- High / Low $ 57.98 / 57.91
- Stock P/E N/A
- Book Value 9.02
- EPS -11.66
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.51 %
- ROE -0.85 %
- 52 Week High 57.98
- 52 Week Low 5.66
About
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$58.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-05 | 2024-11-11 | 2024-08-08 | 2024-05-09 | 2024-03-07 | 2023-11-13 | 2023-08-11 | 2023-05-11 | 2023-03-14 |
| Reported EPS | -0.65 | -0.65 | -0.08 | -1.22 | -0.4738 | -0.71 | -0.79 | -0.8 | -0.82 | -0.66 | -0.76 | -0.64 |
| Estimated EPS | -0.1085 | -0.09 | -0.1361 | -0.3551 | -0.56 | -0.72 | -0.81 | -0.86 | -0.75 | -0.78 | -0.68 | -0.65 |
| Surprise | -0.5415 | -0.56 | 0.0561 | -0.8649 | 0.0862 | 0.01 | 0.02 | 0.06 | -0.07 | 0.12 | -0.08 | 0.01 |
| Surprise Percentage | -499.0783% | -622.2222% | 41.2197% | -243.5652% | 15.3929% | 1.3889% | 2.4691% | 6.9767% | -9.3333% | 15.3846% | -11.7647% | 1.5385% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.92 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: RAPT
2026-02-21 00:47:12
RTW INVESTMENTS, LP has acquired an additional 166,666 shares of RAPT Therapeutics Inc at a price of $33.87 per share, increasing its total holdings to 1,637,165 shares, representing 5.90% of its portfolio. This transaction reflects RTW Investments' confidence in the clinical-stage biopharmaceutical company, which specializes in immunology-based therapies, despite RAPT Therapeutics Inc's low GF Score of 33/100 and poor profitability and growth ranks. The stock has shown strong market momentum with an 81.85% year-to-date price change and is currently trading at $57.92.
2026-02-20 00:59:14
Rapt Therapeutics Inc. has reached a 52-week stock high of $57.87, reflecting a significant 1-year change of 473.91% and strong investor confidence. This surge follows GSK's announcement to acquire Rapt Therapeutics for $2.2 billion ($58 per share), although analysts have offered mixed reactions to the acquisition. The company is recognized for its innovative biotechnology approaches and the potential of its drug ozureprubart.
2026-02-19 23:57:04
Halper Sadeh LLC, an investor rights law firm, is investigating potential violations of federal securities laws and breaches of fiduciary duties related to several company transactions. The firm is looking into the sales of RAPT Therapeutics, Inc. to GSK plc and Amicus Therapeutics, Inc. to BioMarin Pharmaceutical Inc., as well as the mergers of Contango ORE, Inc. with Dolly Varden Silver Corporation and Tamboran Resources Corporation with Falcon Oil & Gas Ltd. Halper Sadeh LLC encourages shareholders of these companies to contact them to discuss their legal rights and options, suggesting insiders may benefit disproportionately and deals might limit competing offers.
2026-02-18 13:27:35
RAPT Therapeutics Inc. (NASDAQ: RAPT) has been identified by ChartMill's technical analysis as a strong candidate for a potential breakout. The stock exhibits excellent technical conditions, with high scores for trend direction, market performance, and moving average positions, indicating it is a market leader in an uptrend. Furthermore, its high pattern quality score suggests it is in a temporary pause after a gain, setting up a clear resistance level and a possible entry point for breakout traders.
2026-02-17 16:27:36
The article "Biggest stock movers Tuesday" includes a snippet of content from MSN. The content itself seems to be missing from the provided input, thus a comprehensive summary of stock movers is not possible.
2026-02-12 01:27:42
Halper Sadeh LLC, an investor rights law firm, is investigating RAPT Therapeutics, Allegiant Travel Company, Lisata Therapeutics, and Mission Produce, Inc. for potential violations of federal securities laws and breaches of fiduciary duties related to their recent or proposed transactions. The firm is concerned that the deals for these companies might not be fair to shareholders, particularly regarding financial benefits to insiders and potential limitations on superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options.
